Provectus Biopharmaceuticals Slides on PV-10 Status Change; PetSmart Sinks to New 52-Week Low


Follow this company

Companies Mentioned

NYSE:PVCT / NASDAQ:PETM
05/22/2014 [ACCESSWIRE]

Provectus Biopharmaceuticals, Inc. (NYSE: PVCT) changed its website to say PV-10 is an "investigational drug for cancer" after the company had previously called it a "breakthrough cancer drug." Provectus was supposed to get a response from the FDA this week about its request to grant PV-10 Breakthrough Therapy status for skin cancer. The company has said not announced anything about the FDA's response.

Provectus Biopharmaceuticals, Inc., a development-stage biopharmaceutical company, is engaged in developing pharmaceuticals for oncology and dermatology indications. The company’s product line includes PV-10, which has completed Phase II study for metastatic melanoma; completed a Phase I study for breast cancer; and is in Phase I protocol expansion for liver metastasis, as well as initiated a Phase I feasibility study to detect immune cell infiltration into melanomas.

Get more information on Provectus Biopharmaceuticals, Inc. and free access to the in depth equity report at: www.TrendingWallStreet.com/stockquote/PVCT

TrendingWallStreet.com wants to help everyday people gain awareness about some of the hottest penny stocks trading in the stock market today. TrendingWallStreet.com releases momentum alerts on companies that you may have never heard about or thought about looking at. Take a few minutes to register with us at http://www.trendingwallstreet.com/ to get full access to our free stock reports.

PetSmart, Inc. (NASDAQ: PETM) shares sank after the company reported mixed first quarter results and also issued weaker than expected profit outlooks for the second quarter and for fiscal 2014. First quarter earnings per share came in at $1.04 and revenue was reported at $1.7 billion. This is compared to expectations of $1.01 and $1.77 billion, respectively. PetSmart has forecast 2nd quarter EPS of 92c-96c, which fell short of the consensus of $1.00. For FY14, the company forecast EPS of $4.29-$4.39, compared to consensus of $4.45.

PetSmart, Inc., together with its subsidiaries, operates as a specialty retailer of products, services, and solutions for pets in the United States, Puerto Rico, and Canada. The company offers consumables, such as pet food, treats, and litter; and hardgoods, which include pet supplies and other goods comprising collars, leashes, health care supplies, grooming and beauty aids, toys, apparel, and pet beds and carriers, as well as aquariums and habitats, accessories, décor, and filters for fish, birds, reptiles, and other small pets. It also provides fresh-water fish, small birds, reptiles, and small pets; and pet services, such as dog training, pet grooming, and pet adoption services.

Get more information on PetSmart, Inc. and free access to the in depth equity report at” www.TrendingWallStreet.com/stockquote/PETM

 

Disclosure: TrendingWallStreet.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.

COMMENTS

Leave a comment...
 * 

Your Name
 *